Burning Rock Biotech's IFRS loss for 3 months of 2022 was CN¥261.388 million, up 52.5% from CN¥171.411 million in the previous year. Revenue increased 27.1% to CN¥135,524 million versus CN¥106,623 million a year earlier.
Burning Rock Biotech's IFRS loss for 3 months of 2022 was CN¥261.388 million, up 52.5% from CN¥171.411 million in the previous year. Revenue increased 27.1% to CN¥135,524 million versus CN¥106,623 million a year earlier. 
ir.brbiotech.com
English (US) 